Positive Phase III readout for Baremsis

15 March 2018

UK-based Acacia Pharma (Euronext: ACPH) says that positive results from a Phase III study of Baremsis (amisulpride injection) as a treatment for established post-operative nausea and vomiting (PONV) have been published in the Online First edition of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists (ASA) ( Kranke et al.). Positive headline results were first announced by the Company in January 2016.

The Phase III trial demonstrated that Baremsis is safe and resulted in a statistically-significant reduction in the emergence of PONV when given in combination with an antiemetic drug from another class to adult patients undergoing elective procedures who are at high risk of PONV.

Acacia Pharma said earlier this month that it had priced its initial public offering on the Brussels stock exchange, raising 40 million euros ($49.09 million), and its shares gained 3.4% to 3.58 euros this morning.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK